PArtial REbreathing for Migraine with Aurabroad
PAREMA · Horizon Europe grant · 2023-11-01–2025-10-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2023-ACCELERATOROPEN-01. CORDIS record →
Objective
Migraine with aura (MA) affects 4% of the global population, causing severe attacks that strongly impact patients’ quality of life.Currently available treatments are often ineffective, contraindicated or prone to side effects, causing 74% of migraine patients to be unsatisfied with their current treatment. This indicates a large unmet clinical need and a significant commercial potential.The Rehaler medical device is a unique, patented, non-drug MA treatment that effectively relieves or aborts a high percentage of migraine attacks by modulating CO2 and O2 levels in the central nervous system. The device has a unique commercial advantage by combining 1) A high treatment effect, 2) A low risk profile, and 3) Simplicity, compactness and affordability.To pave the way for regulatory approval, market launch and wide-scale adoption, we will carry out a large-scale clinical trial to collect gold-standard safety and performance data, while expanding our company team and production capacity.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| REHALER AS | DK | coordinator | €1,481,076 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.